Aberrant Hypermethylation Tumor Suppressor Genes in Pancreatic Endocrine Neoplasms

Annals of Surgery

Volumn 238, Issue 3, 2003, Pages 423-432

  House, Michael G ^a   Herman, James G ^b   Guo, Ming Zhou ^b   Hooker, Craig M ^b   Schulick, Richard D ^a   Lillemoe, Keith D ^a   Cameron, John L ^a   Hruban, Ralph H ^a,b   Maitra, Anirban ^a   Yeo, Charles J ^a,b,c   Eberlein, Timothy J ^d   Pitt, Henry A ^d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTINEOPLASTIC AGENT; GLUTATHIONE TRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; PROTEIN P73; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR MARKER; UVOMORULIN;

ADULT; AGED; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL TYPE; CLINICAL ARTICLE; CONFERENCE PAPER; DISEASE ACTIVITY; DNA METHYLATION; FEMALE; GENE FUNCTION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MALE; PANCREAS CANCER; PANCREAS ENDOCRINE NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ARTICLE; FOLLOW UP; GENETICS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; POLYMERASE CHAIN REACTION; SURVIVAL; TIME;

CARCINOMA, ISLET CELL; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0842289159     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Phan GQ, Yeo CJ, Hruban RH, et al. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998;2:472-482.
2. Yu F, Venzon DJ, Serrano J, et al. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol. 1999;17:615-630.
3. Jensen RT. Pancreatic endocrine tumors: recent advances. Ann Oncol. 1999;10(Suppl 4):170-176.
4. Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422-427.
5. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323-333.
6. Wick MR, Graeme-Cook FM. Pancreatic neuroendocrine neoplasms: a current summary of diagnostic, prognostic, and differential diagnostic information. Am J Clin Pathol. 2001;115(Suppl):S28-S45.
7. Wang EH, Ebrahimi SA, Wu AY, et al. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res. 1998;58:4417-4420.
8. Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab. 2000;85:4373-4378.
9. Bartsch D, Hahn SA, Danichevski KD, et al. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors. Oncogene. 1999;18:2367-2371.
10. Evers BM, Rady PL, Sandoval K, et al. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg. 1994;219:596-601; discussion, 602-604.
11. Chung DC, Smith AP, Louis DN, et al. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications. J Clin Invest. 1997;100:404-410.
12. Chan AO, Kim SG, Bedeir A, et al. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene. 2003;22:924-934.
13. Serrano J, Goebel SU, Peghini PL, et al. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab. 2000;85:4146-4156.
14. Muscarella P, Melvin WS, Fisher WE, et al. Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res. 1998;58:237-240.
15. Chung DC, Brown SB, Graeme-Cook F, et al. Localization of putative tumor suppressor loci by genome-wide allelotyping in human pancreatic endocrine tumors. Cancer Res. 1998;58:3706-3711.
16. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-167.
17. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998;19:187-191.
18. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
19. Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res. 2001;61:3225-3229.
20. House MG, Herman JG, Guo M, et al. Prognostic value of hMLH1 hypermethylation and microsatellite instability in pancreatic endocrine neoplasms. Surgery. 2003; in press.
21. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95:11891-11896.
22. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870-6875.
23. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67-70.
24. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954-5958.
25. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
26. House MG, Guo M, Iacobuzio-Donahue C, et al. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis. 2003;24:193-198.
27. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
28. Peto R, Peto R. Asymptomatically efficient rank invariant test procedures. J Roy Stat. 1972;34:185-206.
29. Larsen F, Gundersen G, Lopez R, et al. CpG islands as gene markers in the human genome. Genomics. 1992;13:1095-1107.
30. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
31. Ueki T, Toyota M, Sohn T, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835-1839.
32. Issa JP. Epigenetic variation and human disease. J Nutr. 2002;132(8 Suppl):2388S-2392S.
33. Ueki T, Toyota M, Skinner H, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res. 2001;61:8540- 8546.
34. Park TJ, Han SU, Cho YK, et al. Methylation of O(6)-methylguanine-DNA methyltransferase gene is associated significantly with K-ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer. 2001;92:2760-2768.
35. Jensen RT. Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment. Curr Opin Oncol. 2000;12:368-377.
36. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, et al. Molecular pathology of pancreatic cancer. Cancer J. 2001;7:251-258.
37. Pfeifer GP, Yoon JH, Liu L, et al. Methylation of the RASSF1A gene in human cancers. Biol Chem. 2002;383:907-914.
38. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79:813-829.